Literature DB >> 17702650

Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines.

Christian A Mohr1, Luka Cîcîn-Saîn, Markus Wagner, Torsten Sacher, Margit Schnee, Zsolt Ruzsics, Ulrich H Koszinowski.   

Abstract

The advances of sequence knowledge and genetic engineering hold a great promise for a rational approach to vaccine development. Herpesviruses are important pathogens of all vertebrates. They cause acute and chronic infections and persist in their hosts for life. In man there are eight herpesviruses known and most of them can be linked to diseases. To date only one licensed vaccine against a human herpesvirus exists and there is no proven successful concept on rational design for herpesvirus vaccines available. Here, we use new reverse genetic systems, based on the 230-kb mouse cytomegalovirus genome to explore new methods of vaccine delivery and of virus attenuation. With regard to virus delivery, we show that the bacterial transfer of the infectious DNA in vivo is theoretically possible but not yet a practical option. With regard to a rational approach of virus attenuation, we consider a selective deletion of viral genes that modulate the immune response of the host.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702650     DOI: 10.1016/j.ijmm.2007.07.008

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  9 in total

1.  Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.

Authors:  Mark R Schleiss; Craig J Bierle; Elizabeth C Swanson; Michael A McVoy; Jian Ben Wang; Zainab Al-Mahdi; Adam P Geballe
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

2.  M94 is essential for the secondary envelopment of murine cytomegalovirus.

Authors:  Silke Maninger; Jens Bernhard Bosse; Frederic Lemnitzer; Madlen Pogoda; Christian A Mohr; Jens von Einem; Paul Walther; Ulrich H Koszinowski; Zsolt Ruzsics
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

Review 3.  Update on the current status of cytomegalovirus vaccines.

Authors:  Heungsup Sung; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

4.  Murine cytomegalovirus perturbs endosomal trafficking of major histocompatibility complex class I molecules in the early phase of infection.

Authors:  Maja Ilić Tomas; Natalia Kucić; Hana Mahmutefendić; Gordana Blagojević; Pero Lucin
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

5.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

6.  An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.

Authors:  Mark R Schleiss; Ryan Buus; K Yeon Choi; Alistair McGregor
Journal:  Future Virol       Date:  2013-12-01       Impact factor: 1.831

7.  An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model.

Authors:  Michael P Leviton; Juan C Lacayo; K Yeon Choi; Nelmary Hernandez-Alvarado; Andrew Wey; Mark R Schleiss
Journal:  Clin Dev Immunol       Date:  2013-08-20

8.  A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis.

Authors:  Peter C L Beverley; Zsolt Ruzsics; Ariann Hey; Claire Hutchings; Simone Boos; Beatrice Bolinger; Emanuele Marchi; Geraldine O'Hara; Paul Klenerman; Ulrich H Koszinowski; Elma Z Tchilian
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

9.  N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

Authors:  Florent Dufour; Thibault Rattier; Sarah Shirley; Gaelle Picarda; Andrei Alexandru Constantinescu; Aymeric Morlé; Al Batoul Zakaria; Guillaume Marcion; Sebastien Causse; Eva Szegezdi; Dirk Michael Zajonc; Renaud Seigneuric; Gilles Guichard; Tijani Gharbi; Fabien Picaud; Guillaume Herlem; Carmen Garrido; Pascal Schneider; Chris Alan Benedict; Olivier Micheau
Journal:  Cell Death Differ       Date:  2017-02-10       Impact factor: 15.828

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.